Retatrutide just demolished Ozempic's record: in Phase 3 trials, it delivered 28.7% average body weight loss at 68 weeks — nearly double the 14.9% Ozempic achieves in the same timeframe.
At-a-Glance Key Takeaways
- Retatrutide is not the same as Ozempic — they are entirely different compounds with different mechanisms.
- Retatrutide hits GLP-1, GIP, and glucagon receptors; Ozempic only hits GLP-1.
- Phase 3 data (TRIUMPH-4, Dec 2025): retatrutide 12mg achieved 28.7% weight loss at 68 weeks.
- Ozempic is FDA-approved and available now; retatrutide is in Phase 3 with approval expected 2027.
- The glucagon component adds fat-burning thermogenesis — not found in Ozempic or tirzepatide.
- Retatrutide shows dramatic liver fat reductions, relevant for people with MASLD.
- Both use weekly subcutaneous injections; GI side effects are similar but slightly higher with retatrutide.
- For researchers: R-30 (retatrutide 30mg) is available from Ascension Peptides.
Ozempic redefined what a weight-loss drug could do. Then tirzepatide raised the bar again. Now retatrutide — Eli Lilly's triple-agonist — has turned both of them into reference points, not benchmarks. This breakdown covers everything you need to know: mechanism, trial data, side effects, dosing, and where these two drugs actually stand in 2026.
Is Retatrutide the Same as Ozempic?
No — and the difference matters. Retatrutide (LY3437943, made by Eli Lilly) and Ozempic (semaglutide, made by Novo Nordisk) share the once-weekly injection format and some GI side effects. That's where the similarity ends.
- Ozempic: contains semaglutide, a GLP-1 receptor agonist — single target.
- Retatrutide: a triple agonist — GLP-1, GIP, and glucagon receptors, all at once.
Adding GIP improves insulin sensitivity and fat metabolism (the same logic behind tirzepatide). Adding glucagon is what separates retatrutide from everything else — it increases energy expenditure and drives hepatic fat oxidation, creating a "burn more AND eat less" effect that single- and dual-agonists can't replicate.
How They Work: Single vs Triple Agonist
Ozempic (Semaglutide): GLP-1 Only
Semaglutide mimics GLP-1, a gut hormone that suppresses appetite at the hypothalamus, slows gastric emptying, and stimulates glucose-dependent insulin release. It's straightforward, well-understood, and works — but it only pulls one lever out of several that control body weight and metabolism.
Retatrutide: GLP-1 + GIP + Glucagon
Retatrutide activates all three simultaneously:
- GLP-1: Appetite suppression, slowed gastric emptying, improved glycemic control — same as Ozempic.
- GIP: Amplifies insulin secretion, improves lipid metabolism, may enhance the appetite-suppressing effects of GLP-1. Tirzepatide already proved GIP+GLP-1 outperforms GLP-1 alone.
- Glucagon: Boosts energy expenditure, promotes fat oxidation in the liver, increases thermogenesis. It's the differentiator — no other approved obesity drug touches this receptor.
Weight Loss Results: The Data Side by Side
Ozempic / Wegovy (Semaglutide)
- STEP 1 trial: 14.9% average weight loss at 68 weeks (Wegovy 2.4mg vs placebo)
- ~50–60% of patients achieved ≥15% weight loss
- SELECT trial (2023): demonstrated 20% reduction in major adverse cardiovascular events — a landmark finding for an obesity drug
- Half-life: ~7 days; steady state in ~4–5 weeks
Retatrutide
- Phase 2 (NEJM, 2023): 24.2% average weight loss at 48 weeks (12mg); 100% of participants lost ≥5%, 83% lost ≥15%
- Phase 3 TRIUMPH-4 (December 2025): 28.7% average weight loss at 68 weeks (12mg) — ~71 lbs average for participants at the highest dose
- Women in Phase 2: 28.5% average loss; men: 21.2%
- 83% of patients on 12mg achieved ≥15% weight loss
- Phase 2a (Nature Medicine, 2024): significant reductions in liver fat, with particular benefit for MASLD (metabolic dysfunction-associated steatotic liver disease)
- Phase 3 cardiovascular markers: improved lipids, blood pressure, and hsCRP — outcome trial data pending
Retatrutide vs Ozempic: Full Comparison
| Feature | Retatrutide | Ozempic (Semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | Triple agonist (GLP-1 + GIP + Glucagon) | Single agonist (GLP-1 only) |
| Phase 3 Weight Loss | ~28.7% at 68 weeks (TRIUMPH-4, 12mg) | ~14.9% at 68 weeks (STEP 1, 2.4mg) |
| Phase 2 Weight Loss | ~24.2% at 48 weeks (12mg) | N/A — already approved |
| Avg Pounds Lost | ~71 lbs (Phase 3, 12mg) | ~34 lbs (Wegovy 2.4mg) |
| Half-Life | ~6 days | ~7 days |
| Dosing Range | 2mg → 12mg/week (subcutaneous) | 0.25mg → 2.4mg/week (subcutaneous) |
| Injection Frequency | Once weekly | Once weekly |
| Liver Fat Reduction | Significant (MASLD trial data, Nature Medicine 2024) | Moderate |
| CV Outcome Data | Improved markers (Phase 3); outcome trial pending | Proven — SELECT trial: 20% MACE reduction |
| Lean Mass Preservation | Better (glucagon component may help preserve muscle) | Standard for GLP-1 class |
| Side Effects | Nausea, diarrhea, vomiting (slightly higher incidence) | Nausea, diarrhea, constipation (well-characterized) |
| Discontinuation Rate | ~12–18% (dose-dependent, Phase 3) | ~7% (STEP trials) |
| FDA Status | Phase 3 (TRIUMPH program); expected approval 2027 | Approved — diabetes 2017, weight loss (Wegovy) 2021 |
| Available Now? | Compounded only (research use) | Yes — by prescription |
| Estimated Cost | TBD (not yet priced for retail) | ~$900–$1,300/month (retail, before insurance) |
| Same drug? | ❌ No — completely different compounds, different companies | |
Side Effects and Safety Profile
Shared GI Side Effects
Both drugs slow gastric emptying, which causes similar GI effects — especially early in treatment:
- Nausea — most common, typically peaks in the first 4–8 weeks
- Diarrhea — usually mild and transient
- Vomiting — dose-related; tends to improve with slower titration
- Constipation — more common with semaglutide
Ozempic Safety Profile
Semaglutide has one of the most documented safety records of any obesity drug. FDA-approved since 2017, it has real-world data from millions of patients. The SELECT trial additionally confirmed cardiovascular benefit — a 20% reduction in MACE (major adverse cardiovascular events) in people with obesity and pre-existing CVD. Discontinuation due to side effects runs ~7% in trials.
Retatrutide-Specific Considerations
- Slightly higher GI side-effect rates than semaglutide, driven by the glucagon component
- Some participants report a mild heart rate increase — glucagon receptor effect
- Discontinuation rates in Phase 3 ran 12–18%, higher than Ozempic's ~7%
- Long-term cardiovascular outcomes trial is ongoing — no proven MACE reduction yet
- The glucagon component may help preserve lean muscle during rapid weight loss — still being quantified
Dosing and Administration
Both drugs use once-weekly subcutaneous injections with slow titration to minimize side effects.
| Phase | Retatrutide Dose | Semaglutide (Wegovy) Dose |
|---|---|---|
| Starting | 2mg weekly (weeks 1–4) | 0.25mg weekly (weeks 1–4) |
| Escalation 1 | 4mg weekly (weeks 5–8) | 0.5mg weekly (weeks 5–8) |
| Escalation 2 | 6mg weekly (optional, weeks 9–12) | 1.0mg weekly (weeks 9–12) |
| Escalation 3 | 8mg weekly (weeks 13–16) | 1.7mg weekly (weeks 13–16) |
| Maximum Dose | 12mg weekly (maintenance) | 2.4mg weekly (maintenance) |
See the full retatrutide dosing schedule guide for protocol details.
Retatrutide and Liver Fat (MASLD)
One area where retatrutide clearly outperforms Ozempic is metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). A Phase 2a trial published in Nature Medicine (Sanyal et al., 2024) found significant reductions in liver fat content with retatrutide treatment — driven by the glucagon receptor's role in hepatic fat oxidation. Previous data from the Phase 2 obesity trial showed reductions in liver fat up to 82% in some participants.
Semaglutide has modest liver fat benefits, but the glucagon receptor pathway gives retatrutide a structural advantage here that's hard to replicate with GLP-1 alone.
Availability in 2026
Ozempic: Available Now
- FDA-approved for type 2 diabetes (Ozempic, 2017) and obesity (Wegovy, 2021)
- Covered by many insurance plans for diabetes management
- Widely available through healthcare providers and telehealth
- Compounded semaglutide has been available but FDA has tightened regulations on compounding
Retatrutide: Still in Trials
- Phase 3 TRIUMPH program ongoing — TRIUMPH-4 results released December 2025
- FDA approval expected 2027 at the earliest
- Available as compounded retatrutide for research purposes from licensed compounding pharmacies and research suppliers
- Developed by Eli Lilly — the same company behind Mounjaro/tirzepatide (Zepbound)
Which Should You Choose?
Choose Ozempic if:
- You need an FDA-approved, available treatment today
- You have type 2 diabetes and need proven glycemic management
- Cardiovascular protection matters and you want the proven SELECT trial backing
- Insurance coverage is a requirement
- You prefer a medication with years of real-world data behind it
Consider retatrutide if:
- You want maximum weight loss potential — the Phase 3 numbers are genuinely unprecedented
- You have MASLD or significant liver fat and want the glucagon-driven hepatic benefit
- Previous GLP-1 treatments gave underwhelming results
- You're comfortable with a research-use compound while Phase 3 data matures
- Lean mass preservation during rapid weight loss is a priority
Before committing to either compound, it's worth reviewing the Ozempic side effects profile in detail — the two differ meaningfully in GI burden, tolerability, and long-term safety data.
